OrbiMed Secures $3 Billion for Healthcare Venture Expansion

OrbiMed Private Investments X captured $1.9 billion to fuel venture capital opportunities within U.S. and European life sciences markets. Simultaneously, OrbiMed Asia Partners VI secured $1 billion, targeting growth equity and venture projects throughout the Asian region. Managing partner Carl Gordon cited the rapid integration of artificial intelligence and the rise of biotech hubs in China as primary drivers for the firm’s continued aggressive expansion.

With over $21 billion in total assets under management, the firm continues to draw capital from a diverse pool of institutional backers, including sovereign wealth funds, university endowments, and pension funds. Managing partner Carter Neild confirmed that the firm’s 150-person team, operating out of 12 global offices, will deploy these resources to support entrepreneurs focused on transformative medical treatments and technology-enabled services.